Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: Evidence for an adipose tissue-vascular loop

Sridevi Devaraj, Natalia J Torok, Mohan R. Dasu, David Samols, Ishwarlal Jialal

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Background and Objective - Inflammation is pivotal in atherosclerosis. C-reactive protein (CRP), in addition to being a cardiovascular risk marker, may also be proatherogenic. We have previously shown that in addition to the liver, human aortic endothelial cells (HAECs) synthesize and secrete CRP. Whereas CRP levels are increased in obesity, metabolic syndrome, and diabetes, levels of adiponectin are reduced in these conditions. We tested the hypothesis that adiponectin reduces CRP synthesis and secretion in HAECs under normoglycemic (5.5 mmol/L glucose) and hyperglycemic conditions (15 mmol/L glucose). Methods and Results - Adiponectin dose-dependently reduced CRP mRNA and protein from HAECs. Adiponectin treatment of HAECs significantly decreased IκB phosphorylation and NFκB binding activity. There was no effect of adiponectin on STAT or C/EBP transcriptional activity. Adiponectin also activated AMP kinase resulting in decreased NFκB activity and decreased CRP mRNA and protein. These effects of adiponectin were mimicked by AICAR, an activator of AMPK, and reversed by inhibition of AMPK. Thus, adiponectin reduces CRP synthesis and secretion from HAECs under hyperglycemia via upregulation of AMP kinase and downregulation of NFκB. Similar findings were observed in rat primary hepatocytes. Conclusions - Thus, in obesity and diabetes, the hypoadiponectinemia could exacerbate the proinflammatory state by inducing CRP production.

Original languageEnglish (US)
Pages (from-to)1368-1374
Number of pages7
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume28
Issue number7
DOIs
StatePublished - Jul 1 2008

Fingerprint

Adiponectin
C-Reactive Protein
Blood Vessels
Adipose Tissue
Endothelial Cells
AMP-Activated Protein Kinases
Obesity
Glucose
Adenylate Kinase
Messenger RNA
Hyperglycemia
Hepatocytes
Atherosclerosis
Proteins
Up-Regulation
Down-Regulation
Phosphorylation
Inflammation
Liver

Keywords

  • Adiponectin
  • Adipose
  • CRP
  • Endothelium

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells : Evidence for an adipose tissue-vascular loop. / Devaraj, Sridevi; Torok, Natalia J; Dasu, Mohan R.; Samols, David; Jialal, Ishwarlal.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 28, No. 7, 01.07.2008, p. 1368-1374.

Research output: Contribution to journalArticle

@article{53880bd4e8ea40e6801c66ad706c704b,
title = "Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: Evidence for an adipose tissue-vascular loop",
abstract = "Background and Objective - Inflammation is pivotal in atherosclerosis. C-reactive protein (CRP), in addition to being a cardiovascular risk marker, may also be proatherogenic. We have previously shown that in addition to the liver, human aortic endothelial cells (HAECs) synthesize and secrete CRP. Whereas CRP levels are increased in obesity, metabolic syndrome, and diabetes, levels of adiponectin are reduced in these conditions. We tested the hypothesis that adiponectin reduces CRP synthesis and secretion in HAECs under normoglycemic (5.5 mmol/L glucose) and hyperglycemic conditions (15 mmol/L glucose). Methods and Results - Adiponectin dose-dependently reduced CRP mRNA and protein from HAECs. Adiponectin treatment of HAECs significantly decreased IκB phosphorylation and NFκB binding activity. There was no effect of adiponectin on STAT or C/EBP transcriptional activity. Adiponectin also activated AMP kinase resulting in decreased NFκB activity and decreased CRP mRNA and protein. These effects of adiponectin were mimicked by AICAR, an activator of AMPK, and reversed by inhibition of AMPK. Thus, adiponectin reduces CRP synthesis and secretion from HAECs under hyperglycemia via upregulation of AMP kinase and downregulation of NFκB. Similar findings were observed in rat primary hepatocytes. Conclusions - Thus, in obesity and diabetes, the hypoadiponectinemia could exacerbate the proinflammatory state by inducing CRP production.",
keywords = "Adiponectin, Adipose, CRP, Endothelium",
author = "Sridevi Devaraj and Torok, {Natalia J} and Dasu, {Mohan R.} and David Samols and Ishwarlal Jialal",
year = "2008",
month = "7",
day = "1",
doi = "10.1161/ATVBAHA.108.163303",
language = "English (US)",
volume = "28",
pages = "1368--1374",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells

T2 - Evidence for an adipose tissue-vascular loop

AU - Devaraj, Sridevi

AU - Torok, Natalia J

AU - Dasu, Mohan R.

AU - Samols, David

AU - Jialal, Ishwarlal

PY - 2008/7/1

Y1 - 2008/7/1

N2 - Background and Objective - Inflammation is pivotal in atherosclerosis. C-reactive protein (CRP), in addition to being a cardiovascular risk marker, may also be proatherogenic. We have previously shown that in addition to the liver, human aortic endothelial cells (HAECs) synthesize and secrete CRP. Whereas CRP levels are increased in obesity, metabolic syndrome, and diabetes, levels of adiponectin are reduced in these conditions. We tested the hypothesis that adiponectin reduces CRP synthesis and secretion in HAECs under normoglycemic (5.5 mmol/L glucose) and hyperglycemic conditions (15 mmol/L glucose). Methods and Results - Adiponectin dose-dependently reduced CRP mRNA and protein from HAECs. Adiponectin treatment of HAECs significantly decreased IκB phosphorylation and NFκB binding activity. There was no effect of adiponectin on STAT or C/EBP transcriptional activity. Adiponectin also activated AMP kinase resulting in decreased NFκB activity and decreased CRP mRNA and protein. These effects of adiponectin were mimicked by AICAR, an activator of AMPK, and reversed by inhibition of AMPK. Thus, adiponectin reduces CRP synthesis and secretion from HAECs under hyperglycemia via upregulation of AMP kinase and downregulation of NFκB. Similar findings were observed in rat primary hepatocytes. Conclusions - Thus, in obesity and diabetes, the hypoadiponectinemia could exacerbate the proinflammatory state by inducing CRP production.

AB - Background and Objective - Inflammation is pivotal in atherosclerosis. C-reactive protein (CRP), in addition to being a cardiovascular risk marker, may also be proatherogenic. We have previously shown that in addition to the liver, human aortic endothelial cells (HAECs) synthesize and secrete CRP. Whereas CRP levels are increased in obesity, metabolic syndrome, and diabetes, levels of adiponectin are reduced in these conditions. We tested the hypothesis that adiponectin reduces CRP synthesis and secretion in HAECs under normoglycemic (5.5 mmol/L glucose) and hyperglycemic conditions (15 mmol/L glucose). Methods and Results - Adiponectin dose-dependently reduced CRP mRNA and protein from HAECs. Adiponectin treatment of HAECs significantly decreased IκB phosphorylation and NFκB binding activity. There was no effect of adiponectin on STAT or C/EBP transcriptional activity. Adiponectin also activated AMP kinase resulting in decreased NFκB activity and decreased CRP mRNA and protein. These effects of adiponectin were mimicked by AICAR, an activator of AMPK, and reversed by inhibition of AMPK. Thus, adiponectin reduces CRP synthesis and secretion from HAECs under hyperglycemia via upregulation of AMP kinase and downregulation of NFκB. Similar findings were observed in rat primary hepatocytes. Conclusions - Thus, in obesity and diabetes, the hypoadiponectinemia could exacerbate the proinflammatory state by inducing CRP production.

KW - Adiponectin

KW - Adipose

KW - CRP

KW - Endothelium

UR - http://www.scopus.com/inward/record.url?scp=46249092855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46249092855&partnerID=8YFLogxK

U2 - 10.1161/ATVBAHA.108.163303

DO - 10.1161/ATVBAHA.108.163303

M3 - Article

C2 - 18451326

AN - SCOPUS:46249092855

VL - 28

SP - 1368

EP - 1374

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 7

ER -